Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMed vs Royal Medical Center

eMed
Graded #398

Higher grade

vs+8
Royal Medical Center
Graded #492

Lower grade

The verdict

eMed takes it — 57.4/100 to 49.4/100.

eMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMed is a digital health platform best known for at-home diagnostics that now runs a clinician-supported GLP-1 weight management program.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueeMed +23
45
22
Dose & formulationRoyal Medical Center +2
40
42
Clinical oversighteMed +21
83
62
Labs & monitoringRoyal Medical Center +21
65
86
FulfillmenteMed +14
62
48
Contract termsEven
55
55
eMed · left barRoyal Medical Center · right bar

The numbers

MetriceMedRoyal Medical Center
WeighScore57.4/10049.4/100
GradeCC
Scorecard rank#398#492
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosed$450/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
eMed

Graded #398 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
  • At-home blood collection makes lab work convenient
  • Clinician review and ongoing side-effect plus adherence support
  • Works with CVS Caremark so eligible employees can buy through benefits
  • Established digital health company with national scale

Where it loses points

  • Distributed mainly via employers, with limited direct cash-pay access
  • No public transparent monthly price for individuals
  • Eligibility and subsidy depend on what the employer chooses to cover
  • Best suited to workforces, not casual self-pay shoppers
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard